

RESEARCH

Open Access



# EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF- $\kappa$ B and Erk1/2 pathways

Cheng Lin<sup>1,2</sup>, Jingfeng Zong<sup>2</sup>, Wansong Lin<sup>3</sup>, Minghui Wang<sup>4</sup>, Yuanji Xu<sup>2</sup>, Rui Zhou<sup>1</sup>, Shaojun Lin<sup>2</sup>, Qiaojuan Guo<sup>2</sup>, Honglin Chen<sup>5</sup>, Yunbin Ye<sup>3,6</sup>, Bin Zhang<sup>4\*</sup> and Jianji Pan<sup>2\*</sup>

## Abstract

**Background:** Epstein-Barr virus (EBV) is ubiquitously associated with nasopharyngeal carcinoma (NPC). EBV encodes two groups of microRNAs (miRNAs) which are divided into *Bam*HI fragment H rightward open reading frame 1 (BHRF1) and *Bam*HI-A rightward transcripts (BART) microRNAs. EBV miR-BART has been found to be involved in the development and progression of NPC. However, so far the role of EBV-miR-BART8-3p in NPC progression remains unknown. This study aimed to investigate the role of EBV-miR-BART8-3p in NPC and explore the underlying mechanisms.

**Methods:** miRNA expression was profiled in NPC and normal nasopharyngeal mucosal specimens using miRNA sequencing. EBV-miR-BART8-3p and RNF38 expression was quantified with qPCR assay. The migration, invasion and metastasis of NPC cells were evaluated using CCK-8, colony-forming, wound-healing, and migration and invasion assays. The expression levels of epithelial-mesenchymal transition (EMT)-related markers, metastasis-related markers and NF- $\kappa$ B and Erk1/2 signaling proteins were determined using Western blotting. Tumorigenic assay was performed to evaluate the pulmonary metastatic ability of NPC cells *in vivo*.

**Results:** EBV BART miRNAs were highly over-expressed and co-expressed in NPC and might be associated with deactivated immune response in NPC according to the sequencing analysis. EBV-miR-BART8-3p expression was significantly higher in human NPC specimens than in normal nasopharyngeal mucosal specimens. EBV-miR-BART8-3p was found to promote NPC migration, invasion and metastasis, drove an EMT process and upregulated expression of metastasis-related proteins expression in NPC cells. Our data showed EBV-miR-BART8-3p directly targeted RNF38 in NPC cells.

(Continued on next page)

\* Correspondence: [bin.zhang@mssm.edu](mailto:bin.zhang@mssm.edu); [panjianji1956@163.com](mailto:panjianji1956@163.com)

<sup>4</sup>Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029, USA

<sup>2</sup>Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350011, Fujian Province, China

Full list of author information is available at the end of the article



(Continued from previous page)

**Conclusion:** The present study demonstrates that EBV-miR-BART8-3p plays a significant role in inducing EMT and promoting metastasis through directly targeting RNF38 in NPC cells via the activation of NF- $\kappa$ B and Erk1/2 signaling pathways. Our findings suggest that EBV-miR-BART8-3p is a potential therapeutic target for NPC.

**Keywords:** Nasopharyngeal carcinoma, Epithelial-mesenchymal transition, Metastasis, Epstein-Barr virus, EBV-miR-BART8-3p, NF- $\kappa$ B signaling, Erk1/2 signaling

## Background

Nasopharyngeal carcinoma (NPC) is the most common primary malignancy in the nasopharynx [1, 2]. Although NPC is rare worldwide [3], this malignancy remains highly prevalent in endemic regions, notably in southern China [4]. Currently, radiotherapy remains the treatment of choice for NPC, and concomitant chemoradiotherapy has been proved to increase the survival [5, 6]. Although 80 to 90% 5-year local control rates have been achieved for NPC, there are still 15 to 30% of patients developing distant metastasis [7]. Elucidation of the mechanisms underlying NPC metastasis in NPC is therefore of great significance to improve the prognosis and treatment outcomes.

Epstein-Barr virus (EBV) has been accepted as an etiological factor for NPC. Almost 100% of non-keratinizing NPC, are associated with EBV infections [1], which accounts for 95% of all NPCs in endemic regions [2]. A set of EBV latent genes have been identified to play an important role in the development of NPC, including three latent membrane proteins (LMP1, LMP2A and LMP2B), EBV nuclear antigen 1 (EBNA1) and EBV-encoded RNAs (EBERs) [3]. However, only three latent proteins (EBNA1, LMP1 and LMP2A) are expressed in type II latency of EBV infection, a predominant form of latency observed in NPC [4]. Whereas EBV-encoded microRNAs (EBV-miRNAs) are detected in most of clinical NPC specimens and cells during all the forms of latency [5–8].

EBV is the first identified human tumor-causing virus that encodes miRNAs. EBV-miRNAs consist of more than 10% of total miRNAs in NPC specimens and EBV-positive NPC C666–1 cells, and increasing evidence shows that EBV-miRNAs contribute to cancer survival [9–13], metastasis [14–18], immune evasion [19, 20] and latency [21–24]. Currently, EBV-miRNAs are divided into two clusters based on their locations, including *Bam*HI fragment H rightward open reading frame 1 (BHRF1) and *Bam*HI-A rightward transcripts (BART) miRNAs. EBV BART miRNAs contain 22 miRNA precursors (termed EBV-miR-BART1 to 22) that produce totally 44 mature miRNAs [6]. Previous studies showed that EBV BART miRNAs were highly overexpressed in clinical specimens and plasma samples of NPC patients and were involved in the development and progression of NPC [5, 25]. However, so

far the role of EBV-miR-BART8-3p in NPC progression remains unknown. This study aimed to investigate the role of EBV-miR-BART8-3p in NPC, and explore the underlying mechanisms.

## Materials and methods

### Ethical approval

This study was approved by the Ethical Review Committee of Fujian Cancer Hospital (approval no. FJZLYY2016–00143). Written informed consent was obtained from all participants following a detailed description of the purpose of the study. All experiments described in this study were conducted in accordance with international and national laws, regulations and guidelines.

### Clinical specimens

Six EBV-positive NPC biopsy specimens and 4 normal nasopharyngeal mucosal specimens were sampled for miRNA sequencing, and another 19 NPC specimens and 10 normal nasopharyngeal specimens were used to quantify EBV-BART8-3p and RNF38 expression. All NPC was diagnosed by pathological examinations, and all specimens were stored in liquid nitrogen for the subsequent experiments.

### Animals

Five-week-old female BALB/c nude mice were purchased from the Medical Experimental Animal Center of Guangdong Province (Guangzhou, China). All mice were housed in a clean facility in the Laboratory Animal Center of Fujian Medical University (Fuzhou, China) and given free access to clean water and food.

### Cell lines and culture

Two EBV-negative NPC cell lines CNE-1 and SUNE-1 and human embryonic kidney (HEK) 293 T cells were purchased from China Center for Type Culture Collection (Wuhan, China), and one EBV-positive C666–1 cell line was kindly presented by Professor Hong lin Chen from the University of Hong Kong. All NPC cells were cultured in RPMI-1640 medium (HyClone; Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) at 37 °C containing 5% CO<sub>2</sub>. HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan,

UT, USA) supplemented with 10% FBS at 37 °C containing 5% CO<sub>2</sub>.

#### RNA sequencing and data analysis

Paired-end (2 × 150 bp) RNA-seq assays were performed from ribosomal RNA depleted total RNA on Illumina HiSeq 2500 system (Illumina; San Diego, CA, USA) according to the standard manufacturer's protocol. The raw sequence reads were aligned to human genome GRCh38 with the star aligner (v2.5.0b) [26]. Then the gene level expression was quantified by feature Counts (v1.4.4) [27] based on GENCODE gene model version p2 release22. Genes with at least 1 count per million (CPM) in at least 1 sample were kept other removed from further analysis. The gene level read counts data was normalized using the trimmed mean of M-values normalization (TMM) method [28] to adjust for sequencing library size difference. Differential gene expression between cancer and control groups was predicted by a linear model analysis using Bioconductor package limma [29]. To adjust for multiple tests, the false discovery rate (FDR) of the differential expression test was estimated using the Benjamini-Hochberg method [30]. Genes with FDR adjusted *p* value ≤ 0.05 and fold change (FC) ≥ 1.2 were considered significant. Heatmap and cluster dendrogram of the significant genes were plotted using R programming language (<https://www.r-project.org/>). Gene ontology (GO) and pathways enriched in the differentially expressed genes were identified by Fisher's exact test (FET) based on the gene set annotation collections from MSigDB [31].

#### miRNA sequencing and data analysis

Total RNA was extracted from NPC specimens and normal nasopharyngeal mucosal specimens using TRIzol reagent (Invitrogen; Carlsbad, CA, USA). The RNA concentration was measured with a NanoDrop2000 Spectrophotometer (NanoDrop Technologies; Wilmington, DE, USA), and the integrity of purified RNA was determined using Agilent 2100 Bioanalyzer (Agilent Technologies; Palo Alto, CA USA). miRNA quantification was evaluated using Hot Start PCR. A small RNA library was built using the Next Multiplex Small RNA Library Prep Set for Illumina (NEB; Ipswich, MA, USA) according to the manufacturer's protocol. Polyacrylamide gel electrophoresis was performed to purify small RNA and to enrich for molecules ranging from 18 to 30 nt. Then, cDNA was synthesized, digested and amplified to set cDNA libraries, followed by purification on a polyacrylamide gel and quantification. Finally, the cDNA libraries were sequenced using standard protocols on an Illumina HiSeq 4000 System (Illumina; San Diego, CA, USA). miRNA annotation was performed in the miRBase database (<http://www.mirbase.org>). Sequencing data were

aligned to the reference human genome (UCSC hg19) and EBV genome (GCF\_000872045.1).

Reads mapped to known miRNAs were identified by searching miRBase database (v21). Novel miRNAs were predicted by miRDeep [32]. Known and novel miRNA expression levels were measured by the number of mapped reads. Similar to the gene level differential expression analysis, differentially expressed miRNAs between cancer and control groups were predicted by limma following library depth normalization by the TMM method.

#### microRNA co-expression network analysis

The weighted network analysis begins with a matrix of the Pearson correlations between all miRNA pairs, then converts the correlation matrix into an adjacency matrix using a power function  $f(x) = x^\beta$ . The parameter  $\beta$  of the power function is determined in such a way that the resulting adjacency matrix (i.e., the weighted co-expression network), is approximately scale-free. To measure how well a network satisfies a scale-free topology, we use the fitting index [33] (i.e., the model fitting index  $R^2$  of the linear model that regresses  $\log(p(k))$  on  $\log(k)$  where  $k$  is connectivity and  $p(k)$  is the frequency distribution of connectivity). The fitting index of a perfect scale-free network is 1. For this dataset, we select the smallest  $\beta$  which leads to an approximately scale free network. The distribution  $p(k)$  of the resulting network approximates a power law:  $p(k) \sim k^{-\gamma}$ .

To explore the modular structures of the co-expression network, the adjacency matrix is further transformed into a topological overlap matrix [33]. As the topological overlap between two genes reflects not only their direct interaction, but also their indirect interactions through all the other genes in the network, previous studies have shown that topological overlap leads to more cohesive and biologically meaningful modules [33, 34]. To identify modules of highly co-regulated microRNAs, we use average linkage hierarchical clustering to group genes based on the topological overlap of their connectivity, followed by a dynamic cut-tree algorithm to dynamically cut clustering dendrogram branches into miRNA modules [35]. To distinguish between modules, each module was assigned a unique color identifier, with the remaining, poorly connected miRNAs colored grey.

#### qPCR assay

The EBV-miR-BART8-3p and RNF38 expression were quantified using qPCR assay. Briefly, total RNA was extracted from NPC biopsy specimens and normal nasopharyngeal mucosal specimens using TRIzol reagent (Invitrogen; Carlsbad, CA, USA), and transcribed into cDNA using miScript II RT Kit (Qiagen; Valencia, CA, USA) following the manufacturer's

instructions. qPCR assay was performed using the miScript SYBR Green PCR Kit (Qiagen). *U6* snRNA and *GAPDH* were served as internal controls for quantifying miRNA and mRNA expression, respectively. The relative quantity of miRNA and mRNA expression was calculated using the  $2^{-\Delta\Delta C_t}$  method. All determinations were repeated in triplicate.

#### Lentiviral transfection

Lentiviral particles (GV369 and Ubi-MCS-SV40-EGFP-IRES-puromycin) containing EBV-miR-BART8-3p precursors and lentiviral particles (GV280 and hU6-MCS-Ubiquitin-EGFP-IRES-puromycin) containing reverse complement of EBV-miR-BART8-3p and their control vectors were constructed by Shanghai Genechem Co., Ltd. (Shanghai, China). CNE-1 and SUNE-1 cells were transfected with a recombinant lentiviral vector GV369 to upregulate EBV-miR-BART8-3p expression (CNE-1-BART8-3p and SUNE-1-BART8-3p cells), and C666-1 cells were transfected with a lentiviral vector GV280 to downregulate EBV-miR-BART8-3p expression (C666-1-BART8-3p cells). The transfection efficiency was checked using qPCR assay.

For the rescue assay, CNE-1-BART8-3p cells and SUNE-1-BART8-3p cells were transfected with the RNF38 lentiviral vector GV358 (Shanghai Genechem Co., Ltd.; Shanghai, China) or a normal control (Shanghai Genechem Co., Ltd.; Shanghai, China).

#### Cell proliferation and colony-forming assays

For cell proliferation assays, cells were seeded onto 96-well plates (Corning, Inc.; Corning, NY, USA) at a density of 1500 cells per well and were incubated at 37 °C containing 5% CO<sub>2</sub> for 1, 2 and 3 days. Subsequently, 10 μl of Cell Counting Kit-8 solution (Dojindo; Dojindo Molecular Technologies, Inc., Tokyo, Japan) was added to each well and incubated for 2 h. Then, the absorbance value (OD) was measured at 450 nm.

For colony-forming assays, cells were seeded onto 6-well plates (Corning, Inc.; Corning, NY, USA) at a density of 1000 cells per well and each group had three replicate wells. Following 2-week incubation, cell colonies were washed twice in PBS, fixed with 100% methanol and stained with crystal violet staining solution (Beyotime Institute of Biotechnology; Shanghai, China) for 15 min for counting.

#### Wound healing assay

Cells were seeded onto 6-well plates (Corning, Inc.; Corning, NY, USA), and artificial wounds were created using a sterile 200 μl plastic tip following serum starvation for 24 h. Then, cells were washed with serum-free medium to remove debris and floating cells. Images of the wounds were captured at 0, 24 and 48 h under an inverted microscope.

#### Cell migration and invasion assays

For cell migration and invasion assays, cells in serum-free medium were transferred to the upper chamber of 8.0 μm pore size (Corning, Inc.; Corning, NY, USA) without or with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), and 20% FBS was added to the bottom chamber. SUNE-1 and CNE-1 cells were incubated in the upper chamber and removed 24 (cell migration assays) or 48 h after incubation (cell invasion assays), respectively, while C666-1 cells were incubated for 48 h in migration and invasion assays. Then, cells on the lower surface of the membrane were fixed and stained. Finally, images were captured and cell numbers were counted using microscopy (100 ×).

#### Western blotting analysis

Western blotting analyses were performed by using standard protocols. Primary antibodies, including rabbit anti-RNF38 polyclonal antibody (1:250; Abcam, Cambridge, MA, USA), rabbit anti-Vimentin monoclonal antibody (1:1000; Abcam), rabbit anti-E-cadherin monoclonal antibody (1:1000; Abcam), rabbit anti-Snail monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-N-cadherin monoclonal antibody (1:5000; Abcam), rabbit anti-MMP2 polyclonal antibody (1:200; Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, USA), rabbit anti-MMP9 monoclonal antibody (1:1000; Abcam), mouse anti-IKKα monoclonal antibody (1:200; Santa Cruz Biotechnology, Inc.), rabbit anti-p-IKKα/β monoclonal antibody (1:1000; Cell Signaling Technology, Inc.; Danvers, MA, USA), rabbit anti-IKKβ monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-IκBα monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-p-IκBα monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), mouse anti-IκBβ monoclonal antibody (1:200; Santa Cruz Biotechnology, Inc.), rabbit anti-p-IκBβ monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), mouse anti-NF-κB monoclonal antibody (1:200; Santa Cruz Biotechnology, Inc.), rabbit anti-p-NF-κB monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-Erk1/2 monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-p-Erk1/2 monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-p-Mek1/2 monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), rabbit anti-p-c-Raf monoclonal antibody (Ser259) (1:1000; Cell Signaling Technology, Inc.), rabbit anti-TAK1 monoclonal antibody (1:1000; Cell Signaling Technology, Inc.), and rabbit anti-p-TAK1 monoclonal antibody (1:1000; Cell Signaling Technology, Inc.) were used. Membranes were incubated with the primary antibodies at 4 °C overnight, followed by incubation with the horseradish

peroxidase (HRP)-conjugated secondary anti-rabbit or anti-mouse IgG antibody (1:3000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature, while rabbit anti-GAPDH polyclonal antibody (1:10000; Abcam) served as a loading control.

#### Bioinformatics analysis and dual-luciferase reporter assay

The potential target genes of EBV-miR-BART8-3p were predicted using two publicly available algorithms RepTar (<http://reptar.ekmd.huji.ac.il/>) and DIANA TOOLS (<http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index>). Then, the predicted candidate targets were confirmed by the software RNAhybrid (<https://bibiserv.cebitec.uni-bielefeld.de/>) with low minimum free energy (MFE) ( $\leq -20.0$ ). To validate whether RNF38 was a direct target of EBV-miR-BART8-3p, wide-type or mutated luciferase reporter vectors of RNF38 were transfected into HEK293T cells with a miR-BART8-3p mimic or normal control. The Firefly and Renilla luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega; Madison, WI, USA) 48 h post-transfection. All measurements were repeated in triplicate.

#### Animal experiments

To evaluate the pulmonary metastatic ability of NPC cells in vivo, 100  $\mu$ l of SUNE-1-BART8-3p cells at a density of  $1.0 \times 10^6$  cells/ml or an equal amount of control cells were intravenously injected into the tail vein of the nude mice. All mice were subjected to fluorescent imaging on anLT-9MACIMSYPLUS whole-body imaging system (Lighttools Research; Encinitas, CA, USA) 6-weeks post-injection and then sacrificed. Pulmonary metastatic lesions were sampled and quantified.

#### Statistical analysis

All statistical analyses were performed using the software SPSS version 24.0 (SPSS, Inc.; Chicago, IL, USA) and Graph Pad Prism 7 (GraphPad; La Jolla, CA, USA) unless stated specifically. Differences of means were tested for significant significance with Student's *t*-test, and the correlation between EBV-miR-BART8-3p

expression and RNF38 mRNA expression was evaluated with Spearman's correlation analysis. A *P* value less than 0.05 was considered statistically significant.

## Results

### EBV BART miRNAs were highly up-regulated and co-expressed in NPC


We first performed differential expression analysis of the miRNA sequencing data from 6 human NPC biopsy specimens and 4 normal nasopharyngeal mucosal specimens (termed control) to systematically uncover miRNAs associated with NPC pathogenesis. The clinical data of NPC cases are showed in Table 1 and TNM stage was listed according to The Union for International Cancer Control / The American Joint Committee on Cancer (UICC/AJCC) 7th of NPC. This dataset has 1315 miRNAs which includes 40 EBV BART miRNAs and 2 EBV BHRF1 miRNAs (i.e., EBV-miR-BHRF1-1 and EBV-miR-BHRF1-2-3p). We identified 30 downregulated miRNAs and 56 upregulated miRNAs in NPC versus control using the criteria of an FC of  $> 1.2$  and an FDR of  $< 0.05$  (Fig. 1a; Additional file 1: Table S1). The two EBV BHRF1 miRNAs and one EBV BART miRNA (EBV-miR-BART19-5p) were not differentially expressed but all the rest 39 differentially expressed EBV BART miRNAs were all upregulated and were highly significantly enriched in the overall 56 upregulated miRNAs (corrected Fisher's Exact Test (FET)  $p = 9.63E-60$ , 22.90 fold enrichment (FE)). Interestingly, the top 35 most significantly upregulated miRNAs identified were all EBV BART miRNAs (Additional file 1: Table S2), indicating that EBV BART miRNAs may play an important role in the development of NPC.

To explore the relationship among the miRNAs, especially the EBV BART miRNAs, we applied the well-established weighted gene co-expression network analysis (WGCNA) [33, 36–40] to the whole miRNA sequencing data. Fig. 1b shows a heat map of the weighted miRNA co-expression network. Twenty five modules with sizes between 3 and 206 microRNAs were identified (Additional file 1: Table S3). Only the turquoise and blue modules are enriched for differentially expressed miRNAs (DEMs) in NPC versus control. Note that the turquoise module comprised of 206 microRNAs

**Table 1** The clinical data of six NPC samples for miRNA sequencing

Number	Sex	Age	Histology	T	N	M	TNM	EBV
NPC1	Male	63	Nonkeratinizing undifferentiated	4	3	0	IVb	+
NPC2	Female	21	Nonkeratinizing undifferentiated	3	3	0	IVb	+
NPC3	Male	23	Nonkeratinizing undifferentiated	2	1	0	II	+
NPC4	Male	61	Nonkeratinizing undifferentiated	1	3	1	IVc	+
NPC5	Female	24	Nonkeratinizing undifferentiated	3	1	0	III	+
NPC6	Female	46	Nonkeratinizing undifferentiated	2	1	0	II	+

Abbreviations: NPC nasopharyngeal carcinoma, EBV Epstein-Barr virus



includes 39 of all the 40 EBV BART microRNAs (corrected FET  $p = 1.32E-30$ , 6.2 FE). The only EBV BART miRNA that is not in the turquoise module is EBV-miR-BART19-5p, the only EBV BART miRNA was not differentially expressed in NPC versus control. Interestingly, the blue module is only enriched for the downregulated miRNAs (corrected FET  $p = 0.014$ , 3 FE) while the turquoise module is enriched for both upregulated (corrected FET  $p = 2.18E-44$ , 6.27 FE) and down-regulated ones (corrected FET  $p = 1.52E-5$ , 3.6 FE), as shown in Additional file 1: Table S4.

**EBV BART miRNAs are associated with deactivated immune response in NPC**

To understand the downstream pathways regulated by miRNAs that may potentially drive NPC pathogenesis, we sought out to analyze the matched transcriptomic data from the same set of samples to identify DEGs in

NPC versus control. We identified 2294 downregulated and 1286 upregulated genes in NPC versus control (Additional file 1: Table S5) at FDR  $\leq 0.05$  and FC  $\geq 1.2$ . The genes upregulated in NPC were most enriched for the cell cycle related functional ontology terms (2.9-FE, corrected FET  $P = 2.21E-31$ ), while those downregulated in NPC versus normal control were most enriched for immune response related pathways including lymphocyte activation (3.3-FE, corrected FET  $P = 1.91E-20$ ), immune system process (1.8-FE, corrected FET  $P = 1.75E-18$ ), leukocyte activation (3-FE, corrected FET  $P = 1.75E-18$ ), cell activation (2.6-FE, corrected FET  $P = 6.59E-18$ ), and immune response (2.0-FE, corrected FET  $P = 4.59E-18$ ), as shown in Additional file 1: Table S6 and Additional file 2: Figure S1.

Meanwhile, we identified the genes significantly negatively correlated with each miRNA. These

miRNA-correlation gene (MCG) signatures were then tested for enrichment of the DEG signature between NPC and normal control. Surprisingly, the MCG signatures for all the EBV BART microRNAs up-regulated in NPC versus control were highly significantly enriched for the DEGs (corrected FET  $P < 1.53E-272$ ,  $FE > 6.1$ ; Additional file 1: Table S7), suggesting that the activation of EBV BART miRNAs dramatically shut down the immune defense system in NPC.


**EBV-miR-BART8-3p is upregulated in human NPC specimens**

EBV-miR-BART8-3p is the most up-regulated EBV BART miRNAs in NPC ( $FC = 1782.9$ ,  $p = 4.24E-12$ ,  $FDR = 5.48E-09$ ; Fig. 1c, Additional file 1: Table S2). To confirm BART8-3p expression by RNA sequencing, we further examined BART8-3p expression in NPC and normal nasopharyngeal mucosal specimens (CTRL). Data indicated that BART8-3p was nearly undetectable in CTRL, while strongly over-expressed in NPC (Fig. 2a). Of note, among top 10 upregulated EBV BART miRNAs, BART 16, 7, 9, 2, 1, 22, 3 and 6, have

been reported to be associated with the development of NPC [41]. BART8-5 was suggested to cause progression of nasal NK-cell lymphoma [42]. We wonder whether BART8-3p plays a role in the carcinogenesis of NPC. Based on miRNA sequencing results and previous studies, we focused on exploring potential function of BART8-3p in NPC.

**EBV-miR-BART8-3p promotes NPC migration, invasion and metastasis in vitro and in vivo**

To investigate the function of EBV-miR-BART8-3p in NPC, two EBV-negative NPC cell lines CNE-1 and SUNE-1 were transfected with lentiviral vectors containing EBV-miR-BART8-3p precursors, and qPCR assay showed higher EBV-miR-BART8-3p expression in NPC cells transfected with EBV-miR-BART8-3p precursors than in those transfected with control vectors ( $P < 0.001$ ) (Fig. 2b). Wound-healing and migration and invasion assays revealed that upregulation of EBV-miR-BART8-3p expression promoted NPC cell migration ( $P < 0.01$ ) and invasion ( $P < 0.001$ ) compared to control vectors-transfected cells (Fig. 2c and d), while downregulation of EBV-miR-BART8-3p



**Fig. 2** EBV-miR-BART8-3p promotes NPC cell migration and invasion in vitro and lung metastasis in vivo. **a** qPCR assay reveals higher EBV-miR-BART8-3p expression in NPC specimens than in normal nasopharyngeal mucosal specimens (CTRL). **b** qPCR assay reveals higher EBV-miR-BART8-3p expression in NPC cells transfected with EBV-miR-BART8-3p precursors than in those transfected with control vectors. miRNA levels are normalized to U6 snRNA expression. **c** Representative images and quantification of the wound-healing assay in CNE-1 and SUNE-1 cells. **d** Representative images and quantification of migration and invasion assays in CNE-1 and SUNE-1 cells. **e** Representative images and quantification of the wound-healing assay in C666-1 cells. **f** Representative images and quantification of migration and invasion assays in C666-1 cells. ND, not detectable. Data is presented as the mean  $\pm$  SD. \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$

suppressed EBV-positive NPCC666–1 cell migration ( $P < 0.01$ ) and invasion ( $P < 0.01$ ) (Fig. 2e and f). However, no significant differences were detected between GV369- or GV280-transfected NPC cells and control vectors-transfected cells in terms of cell proliferation or cell colonies (Additional file 2: Figure S2).

To assess the pulmonary metastatic ability of EBV-miR-BART8-3p in vivo, we modeled pulmonary metastasis of NPC in nude mice by inoculation of SUNE-1-BART8-3p cells or control vector-transfected SUNE-1 cells into the tail veins of nude mice. We found more metastatic tumor nodules in the lung of mice injected with SUNE-1-BART8-3p cells than injection with control vector-transfected SUNE-1 cells ( $P < 0.05$ ) (Fig. 3a and b), and a greater weight of lungs was measured in mice inoculated with SUNE-1-BART8-3p cells than injection with control vector-transfected SUNE-1 cells ( $P < 0.05$ ) (Fig. 3c and d). Taken together, these results suggest that EBV-miR-BART8-3p upregulation promotes NPC cell migration, invasion and metastasis.

#### EBV-miR-BART8-3p upregulation promotes epithelial-mesenchymal transition (EMT) and increases metastasis-related markers expression


Since EMT is closely associated with NPC metastasis [14, 15], we then examined the role of EBV-miR-BART8-3p in EMT of NPC cells. The expression of EMT- and metastasis-related markers was determined in CNE-1 and

SUNE-1 cells. Western blotting showed that upregulation of EBV-miR-BART8-3p caused a reduction in the E-cadherin expression and an increase in the Snail, N-cadherin, Vimentin, MMP2 and MMP9 expression (Fig. 4b). In addition, the NPC cells overexpressing EBV-miR-BART8-3p displayed a mesenchymal-like morphology, while control vectors-transfected NPC cells showed an epithelial-like morphology (Fig. 4b).


Conversely, downregulation of EBV-miR-BART8-3p had the opposite effects in EBV-positive NPC C666–1 cells. EBV-miR-BART8-3p knockdown resulted in a reduction in Snail, N-cadherin and Vimentin expression and an increase in E-cadherin expression, and impeded the EMT-like process in NPC cells (Fig. 4). Taken together, our findings suggest that EBV-miR-BART8-3p drives an EMT process and upregulates metastasis-related proteins in NPC cells.

#### EBV-miR-BART8-3p induces NPC cell metastasis by activating the NF- $\kappa$ B and Erk1/2 pathways

To address the mechanisms underlying miR-BART8-3p-driving metastasis in NPC, we determined the expression of key proteins in the NF- $\kappa$ B and Erk1/2 signaling pathways. Western blotting showed that upregulation of EBV-miR-BART8-3p increased the total and phosphorylation expression of TAK1, p65, IKK $\alpha$ , IKK $\beta$  and IKK $\alpha/\beta$ , and reduced the I $\kappa$ B $\beta$ , p-I $\kappa$ B $\beta$ , I $\kappa$ B $\alpha$  and p-I $\kappa$ B $\alpha$  expression; in addition, the Erk1/2, p-c-Raf,








p-MEK1/2 and p-Erk1/2 expression was also elevated following EBV-miR-BART8-3p upregulation (Fig. 5a). On the contrary, downregulation of EBV-miR-BART8-3p resulted in opposite effects in C666-1 cells (Fig. 5b). Collectively, our data indicate that EBV-miR-BART8-3p mediates NPC cell metastasis through activating the NF-κB and Erk1/2 signaling pathways.

**EBV-miR-BART8-3p directly targets RNF38 in NPC cells**

Then, we predicted the target genes of EBV-miR-BART8-3p. Bioinformatics analysis showed that the 3'-UTR region of the gene *RNF38* was complementary

with the seed sequences of EBV-miR-BART8-3p and *RNF38* had the lowest MFE (Fig. 6a). Firstly, we quantified endogenous *RNF38* protein expression using Western blotting, and the *RNF38* protein was found to be significantly downregulated in both CNE-1-BART8-3p and SUNE-1-BART8-3p cells (Fig. 6b). Subsequently, we cloned the wild-type or mutant-type 3'-UTR of *RNF38* into luciferase reporter vectors, and the luciferase activity was found to be reduced significantly in HEK293 cells transfected with the wild-type 3'-UTR of *RNF38* ( $P < 0.001$ ), while no changes were seen in the cells transfected with the mutant-type



(Fig. 6c), suggesting that RNF38 is regulated by EBV-miR-BART8-3p.

To further quantify the RNF38 expression, we determined *RNF38* mRNA expression in 19 NPC specimens and 10 normal nasopharyngeal specimens, and examined the correlation between EBV-miR-BART8-3p and *RNF38* expression in the 19 NPC specimens. qPCR assay showed significantly lower RNF38 expression in NPC specimens than in normal nasopharyngeal specimens ( $P < 0.001$ ) (Fig. 6d), and Spearman's correlation analysis revealed a negative correlation between EBV-miR-BART8-3p and *RNF38* expression ( $P = 0.001$ ) (Fig. 6e). Taken together, these data indicate that EBV-miR-BART8-3p inhibits *RNF38* expression in NPC through directly targeting *RNF38*.


**Restored RNF38 rescues the phenotypes induced by EBV-miR-BART8-3p overexpression**

To further confirm the functions of *RNF38* in the tumor-promoting effects of EBV-miR-BART8-3p, we rescued RNF38 expression in CNE-1-BART8-3p and SUNE-1-BART8-3p cells. The introduction of exogenous *RNF38* significantly reduced NPC cell migration and invasion (Fig. 7a). Consistent with this biological phenotype, reinstallation of RNF38 reversed EMT and expression of metastasis-related markers by EBV-miR-BART8-3p (Fig. 7b). These data strongly support our hypothesis that *RNF38* is an important mediator of EBV-miR-BART8-3p-induced NPC cell migration and invasion (Fig. 7c).


**Discussion**

EBV infection has been proved to be strongly associated with a variety of lymphoid and epithelial malignancies [3], notably NPC. Since the EBV-miRNAs were firstly discovered in 2004, there are 44 mature EBV BART miRNAs identified to date [43]. Our report showed that a vast majority (97.5% or 39) of the 40 EBV BART miRNAs profiled in this study were significantly upregulated in NPC and further study suggested that these upregulated EBV BART miRNAs were all co-expressed in the same gene module according to WGCNA. In addition, the analysis of DEGs and MCG signatures revealed that EBV BART miRNAs may be involved in immune response, which is little known until now [19, 20].

So far, a few EBV BART miRNAs have been investigated and partially defined in NPC. EBV-miR-BART20-5p, EBV-miR-BART5 and EBV-miR-BART cluster I (miR-BART1-5p, miR-BART16 and miR-BART17-5p) were reported to inhibit apoptosis of NPC cells by targeting BAD, PUMA and LMP1, respectively [9, 10, 13] while miR-BART22 and miR-BART2-5p have been found to contribute to immune evasion through targeting LMP2A and MICB, respectively [19, 20]. Additionally, miR-BART18-5p and miR-BART2 have shown regulatory effects on viral latency by inhibiting MAP3K2 and BALF5 [22, 23]. However, there is little knowledge on the roles of EBV BART miRNAs in metastasis of NPC [26], and the oncogenic and tumor suppressive



**Fig. 6** RNF38 is a direct target of EBV-miR-BART8-3p. **a** EBV-miR-BART8-3p and its putative binding sequence in 3'UTR of RNF38 mRNA, and mutations are generated as indicated. **b** Quantification of RNF38 protein expression by Western blotting in CNE-1, SUNE-1 and C666-1 cells. **c** The relative luciferase activity in HEK293 cells after co-transfection with wild-type (WT) or mutant (MT) RNF38 3'UTR reporter genes and EBV-miR-BART8-3p or control. **d** Relative RNF38 expression is quantified in 10 normal nasopharyngeal specimens and 19 NPC specimens by qPCR, and GAPDH serves as an internal control. **e** Spearman's correlation analysis reveals a negative correlation between the EBV-miR-BART8-3p and RNF38 expression in NPC specimens ( $n = 19$ )



activities of EBV BART miRNAs remain unknown. Previous studies have demonstrated that miR-BART1, miR-BART7-3p, miR-BART9 and miR-BART10-3p induce tumor metastasis by targeting PTEN, E-cadherin and BTRC, respectively [14–17]. However, the role of EBV-miR-BART8-3p is still unknown in NPC. Our findings showed that EBV-miR-BART8-3p was the most up-regulated EBV BART miRNA and it contributed to NPC metastasis by targeting *RNF38*. A recent study reported that miR-BART6-3p inhibits NPC cell metastasis and invasion by targeting long non-coding RNA [18]. Therefore, like human miRNAs, EBV BART miRNAs also constitute a complex miRNA regulatory network and have shown both positive and negative effects on metastatic progression in NPC [44]. It is therefore of great significance to investigate how EBV BART miRNAs are generated and whether they act as oncogenes or tumor suppressors in metastatic progression.

EMT is considered to be a key part of tumor migration and invasion [45]. Until now, few studies have shown the crucial role of EBV BART miRNAs during the process of EMT in NPC, including EBV-miR-BART1, EBV-miR-BART7-3p, EBV-miR-BART9 and EBV-miR-BART10-3p [14–17]. To our knowledge, the present study is the first report demonstrating that EBV-miR-BART8-3p upregulation facilitated EMT, leading to the metastasis of NPC cells. In addition, upregulation of EBV-miR-BART8-3p increased the expression of EMT-related markers and metastasis-related proteins, while downregulation of EBV-miR-BART8-3p attenuated EMT and reduced the expression of EMT-associated proteins. Further studies, however, to investigate the proportions of EBV BART miRNAs and the mechanisms underlying the role of EBV BART miRNAs during the process of EMT in NPC seem justified.

Increasing evidence suggests that NF- $\kappa$ B signaling plays a crucial role in maintaining EBV latency in NPC cells through regulating EBV BART miRNAs and lncRNAs [46], and NF- $\kappa$ B activation is essential in the pathogenesis and progression of NPC [47, 48]. Moreover, NF- $\kappa$ B and Erk1/2 signaling pathways have been found to be vital for EMT and metastasis, along with the upregulation of MMPs [45, 49–51]. It is therefore hypothesized that NF- $\kappa$ B and Erk1/2 signaling is involved in the process of EBV-miR-BART8-3p-induced metastasis in NPC. Our data supported our hypothesis that upregulation of EBV-miR-BART8-3p induced NPC metastasis by activating the NF- $\kappa$ B and Erk1/2 signaling pathways, while downregulation of EBV-miR-BART8-3p had the opposite effects. Of note, previous studies have shown that EBV-miR-BART1 activates PI3K-AKT, FAK-p130<sup>Cas</sup> and MAPK-ERK1/2 pathways, miR-BART10-3p activates  $\beta$ -catenin/Snail signaling and miR-BART7 activates PI3K/AKT and p-GSK-3 $\beta$ -ser9 signaling to promote NPC metastasis [14–16]. In agreement with EBV-miR-BART1, we found that Erk1/2 signaling was closely associated with the metastasis in NPC. Interestingly, we also found, for the first time, that NF- $\kappa$ B signaling contributed to EBV-miR-BART8-3p-induced NPC metastasis. Further studies to examine the mechanisms underlying the contribution of NF- $\kappa$ B signaling to the metastasis of NPC are warranted.

RING finger protein family is involved in a variety of diverse biological processes, including oncogenesis, signal transduction, apoptosis, development and viral infection [52]. *RNF38*, located at chromosome 9 (9p 13), is a member of the RING finger protein family [52]. It is reported that chromosome 9p loss was a key event during the pathogenesis of NPC and frequently deleted in multiple cancers, such as lung cancer [53, 54], hepatocellular carcinoma [55],

squamous cell head and neck cancer [56] and NPC [57]. Previous studies have shown that RNF38 might modify p53 [58, 59] and was associated with the neuronal activity [60]. However, the role of *RNF38* in cancer remains unknown until now. Our data showed that RNF38 might act as a tumor suppressor in NPC.

Our previous study reported that circulating EBV BART miRNAs might be used as biomarkers for early diagnosis and prognosis of NPC [25]. Therefore, we hypothesize that EBV-miR-BART8-3p may be predictive of prognosis in NPC. Further understanding of the role and the potentially clinical value of *RNF38* in the carcinogenesis of NPC and the potential clinical value of EBV-miR-BART8-3p in NPC requires further investigations. Since a growing number of miRNAs and their targeting genes have been identified [61] and they form complex regulatory miRNA network as we demonstrated here, further study of regulatory relationships between EBV-miR-BART8-3p and its target genes in NPC are warranted. Moreover, future studies should also examine the relationships between upregulated EBV BART miRNAs and deactivated immune response genes as well as the relationships between up-regulated genes and cell cycle related processes in NPC.

## Conclusions

The results of the present study demonstrate that EBV-miR-BART8-3p is upregulated in human NPC specimens, and EBV-miR-BART8-3p overexpression facilitates EMT, invasion and migration through directly targeting *RNF38* in NPC cells, via the activation of NF- $\kappa$ B and Erk1/2 signaling pathways. Our findings suggest that EBV-miR-BART8-3p may be a promising therapeutic target for NPC.

## Additional files

**Additional file 1: Table S1.** miRNAs differentially expressed in NPC versus control. **Table S2.** The top 20 most significantly up-regulated microRNAs in NPC. **Table S3.** Module assignment for microRNAs. **Table S4.** Enrichment of differentially expressed microRNAs in the coexpressed microRNA module. **Table S5.** Differentially expressed genes in NPC versus control (NNPC). **Table S6.** Gene ontology and pathways enriched in the up- and down-regulated genes. The functional annotation gene sets were from the MSigDB database. FE, fold enrichment. P value, *P* value was computed from Fisher's exact test. P<sub>adj</sub>, adjusted *P* value computed with Benjamini-Hochberg's false discovery rate approach. **Table S7.** Enrichment of the differentially expressed gene signature in the microRNA-correlated gene signatures. (XLSX 732 kb)

**Additional file 2: Figure S1.** Gene ontology terms enriched in the up- and down-regulated gene signatures. The genes up-regulated in NPC are involved in cell cycle, neurogenesis and cell junction activities while those down-regulated are associated with immune response, suggesting activated cell proliferation and mitosis but inhibited immune defense in NPC.

**Figure S2.** Upregulation of EBV-miR-BART8-3p shows no clear-cut effects on NPC cell proliferation in vitro. a, the effect of EBV-miR-BART8-3p on NPC CNE-1 and SUNE-1 cell proliferation is examined by CCK-8 assay; b, representative pictures (left panel) and quantification (right panel) of the colony-forming assays in CNE-1 and SUNE-1 cells. NS, no significant. Data are presented as mean  $\pm$  SD. (DOCX 957 kb)

## Abbreviations

AJCC: The American Joint Committee on Cancer; BART: BamHI-A rightward transcripts; BHRF1: *Bam*HI fragment H rightward open reading frame 1; DEMs: differentially expressed miRNAs; EBERs: EBV-encoded RNAs; EBNA1: EBV nuclear antigen 1; EBV: Epstein-Barr virus; EBV-miRNAs: EBV-encoded microRNAs; EMT: Epithelial-mesenchymal transition; FC: Fold change; FDR: False discovery rate; FET: Fisher's Exact Test; GO: Gene ontology; LMP1: Latent membrane proteins 1; LMP2A: Latent membrane proteins 2A; LMP2B: Latent membrane proteins 2B; MCG: miRNA-correlation gene; MFE: Minimum free energy; miRNAs: microRNAs; NPC: Nasopharyngeal carcinoma; TOM: Topological overlap matrix; UICC: The Union for International Cancer Control; WGCNA: Weighted gene co-expression network analysis

## Acknowledgments

Not applicable.

## Author contributions

All authors had full access to the data and participated in the design, analysis and interpretation of the data. CL, JJP and BZ were responsible for drafting the manuscript. All of the authors reviewed the manuscript before submission. All authors have read and approved the manuscript.

## Funding

This study was supported by the National Natural Science Foundation of China (grant nos. U1405221, 81470134 and 81341108), the Science and Technology Project of Fujian Province (grant nos. 2015Y0051 and 2018 J01275), the Medical Innovation Project of Fujian Province (grant no. 2015-CX-6), the Fujian Provincial Health and Family Planning Commission (grant no. 2012-1-6), the Research Grants Council of the Hong Kong SAR (grant no. 17154516 & C7027-16G), the Health and Medical Research Fund (grant no. 14131032) and the Areas of Excellence Scheme of the University Grants Committee (grant no. AoE/M-06/08).

## Availability of data and materials

All data pertaining to this study can be accessed upon request by contact with the corresponding author.

## Ethics approval and consent to participate

This study was approved by the Ethical Review Committee of Fujian Cancer Hospital (approval no. FJZLY2016-00143). Written informed consent was obtained from all participants following a detailed description of the purpose of the study. All experiments described in this study were conducted in accordance with international and national laws, regulations and guidelines.

## Consent for publication

All authors consent for publication.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Fujian Medical University, Fuzhou 350108, Fujian Province, China.

<sup>2</sup>Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350011, Fujian Province, China.

<sup>3</sup>Laboratory of Immuno-Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350011, Fujian Province, China.

<sup>4</sup>Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029, USA. <sup>5</sup>State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology and the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The University of Hong Kong, Hong Kong, SAR, China. <sup>6</sup>Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian, China.

Received: 26 September 2018 Accepted: 7 November 2018

Published online: 26 November 2018

## References

- Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. *Annu Rev Pathol.* 2006;1:375–404.
- Wei WJ, Sham JS. Nasopharyngeal carcinoma. *Lancet.* 2005;365(9476):2041–54.
- Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. *Nat Rev Cancer.* 2004;4(10):757–68.
- Yang HJ, Huang TJ, Yang CF, Peng LX, Liu RY, Yang GD, et al. Comprehensive profiling of Epstein-Barr virus-encoded miRNA species associated with specific latency types in tumor cells. *Viro J.* 2013;10:314.
- Chen SJ, Chen GH, Chen YH, Liu CY, Chang YS, et al. Characterization of Epstein-Barr Virus miRNAome in Nasopharyngeal Carcinoma by Deep Sequencing. *Plos One.* 2010;5(9):e12745.
- Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. *J Virol.* 2009;83(5):2357–67.
- Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of Epstein-Barr virus are expressed at dramatically differing levels among cell lines. *Virology.* 2009;386(2):387–97.
- Zhu JY, Pfuhi T, Motsch N, Barth S, Nicholls J, Grasser F, et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. *J Virol.* 2009;83(7):3333–41.
- Kim H, Choi H, Lee SK. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. *Cancer Lett.* 2015;356(2 Pt B):733–42.
- Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. *J Exp Med.* 2008;205(11):2551–60.
- Qiu J, Smith P, Leahy L, Thorley-Lawson DA. The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo. *PLoS Pathog.* 2015;11(1):e1004561.
- Lei T, Yuen KS, Xu R, Tsao SW, Chen H, Li M, et al. Targeting of DICE1 tumor suppressor by Epstein-Barr virus-encoded miR-BART3\* microRNA in nasopharyngeal carcinoma. *Int J Cancer.* 2013;133(1):79–87.
- Lo AK, KF T, Lo KW, Lung RW, Hui JW, Liao G, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. *Proc Natl Acad Sci U S A.* 2007;104(41):16164–9.
- Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. *Oncogene.* 2015;34(17):2156–66.
- Cai L, Ye Y, Jiang Q, Chen Y, Lyu X, Li J, et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. *Nat Commun.* 2015;6:7353.
- Yan Q, Zeng Z, Gong Z, Zhang W, Li X, He B, et al. Ebv-mir-bart10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC. *Oncotarget.* 2015;6(39):41766–82.
- Hsu CY, Yi YH, Chang KP, Chang YS, Chen SJ, Chen HC. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. *PLoS Pathog.* 2014;10(2):e1003974.
- He B, Li W, Wu Y, Wei F, Gong Z, Bo H, et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103. *Cell Death Dis.* 2016;7(9):e2353.
- Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. *Neoplasia.* 2009;11(11):1174–84.
- Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. *Cell Host Microbe.* 2009;5(4):376–85.
- Jung YJ, Choi H, Kim H, Lee SK. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1. *J Virol.* 2014;88(16):9027–37.
- Qiu J, Thorley-Lawson DA. EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. *Proc Natl Acad Sci U S A.* 2014;111(30):11157–62.
- Barth S, Pfuhi T, Mamiani A, Eshes C, Roemer K, Kremmer E, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. *Nucleic Acids Res.* 2008;36(2):666–75.
- Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatziogeorgiou A, et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. *J Biol Chem.* 2010;285(43):33358–70.
- Zhang G, Zong J, Lin S, Verhoeven RJ, Tong S, Chen Y, et al. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. *Int J Cancer.* 2015;136(5):E301–12.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15–21.
- Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923–30.
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139–40.
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B Methodol.* 1995;57(1):289–300.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545–50.
- An J, Lai J, Lehman ML, Nelson CC. miRDeep\*: an integrated application tool for miRNA identification from RNA sequencing data. *Nucleic Acids Res.* 2013;41(2):727–37.
- Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat Appl Genet Mol Biol.* 2005;4:Article17.
- Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL. Hierarchical organization of modularity in metabolic networks. *Science.* 2002;297(5586):1551–5.
- Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the dynamic tree cut library for R. *Bioinformatics.* 2007.
- Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. *Nature.* 2008;452(7186):423–8.
- Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, et al. A functional genomics predictive network model identifies regulators of inflammatory bowel disease. *Nat Genet.* 2017;49(10):1437–49.
- Wang M, Roussos P, McKenzie A, Zhou X, Kajiwara Y, Brennand K, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. *Genome medicine.* 2016;8(104).
- Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezniukov Alexei A, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell.* 2013;153(3):707–20.
- Zhu J, Zhang B, Smith EN, Drees B, Brem RB, Kruglyak L, et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. *Nat Genet.* 2008;40(7):854–61.
- Wang Y, Guo Z, Shu Y, Zhou H, Wang H, Zhang W. BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma. *Eur J Cancer Prev.* 2017;26(2):144–50.
- Huang WT, Lin CW. EBV-encoded miR-BART20-5p and miR-BART8 inhibit the IFN-gamma-STAT1 pathway associated with disease progression in nasal NK-cell lymphoma. *Am J Pathol.* 2014;184(4):1185–97.
- Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. *Science.* 2004;304(5671):734–6.
- Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. *Nat Cell Biol.* 2013;15(6):546–54.
- Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol.* 2014;15(3):178–96.
- Verhoeven RJ, Tong S, Zhang G, Zong J, Chen Y, Jin DY, et al. NF-kappaB signaling regulates expression of Epstein-Barr virus BART MicroRNAs and long noncoding RNAs in nasopharyngeal carcinoma. *J Virol.* 2016;90(14):6475–88.
- Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. *Nat Commun.* 2017;8:141e21.

48. Zheng H, Dai W, Cheung AK, Ko JM, Kan R, Wong BW, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-kappaB pathway regulators in nasopharyngeal carcinoma. *Proc Natl Acad Sci U S A*. 2016;113(40):11283–8.
49. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. *Cancer Res*. 2010;70(2):832–41.
50. Yang J, Lv X, Chen J, Xie C, Xia W, Jiang C, et al. CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway. *Oncotarget*. 2016;7(13):15632–47.
51. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. *J Clin Invest*. 2004;114(4):569–81.
52. Eisenberg I, Hochner H, Levi T, Yelin R, Kahan T, Mitrani-Rosenbaum S. Cloning and characterization of a novel human gene RNF38 encoding a conserved putative protein with a RING finger domain. *Biochem Biophys Res Commun*. 2002;294(5):1169–76.
53. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. *Cancer Res*. 2000;60(17):4894–906.
54. Dai W, Zheng H, Cheung AK, Lung ML. Genetic and epigenetic landscape of nasopharyngeal carcinoma. *Chin Clin Oncol*. 2016;5(2):16.
55. Liew CT, Li HM, Lo KW, Leow CK, Lau WY, Hin LY, et al. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma. *Int J Cancer*. 1999;81(3):319–24.
56. Jefferies S, Edwards SM, Hamoudi RA, A'Hern R, Foulkes W, Goldgar D, et al. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. *Br J Cancer*. 2001;85(9):1383–6.
57. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. *Semin Cancer Biol*. 2002;12(6):451–62.
58. Sheren JE, Kassenbrock CK. RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53. *Biochem Biophys Res Commun*. 2013;440(4):473–8.
59. Lunardi A, Di Minin G, Provero P, Dal Ferro M, Carotti M, Del Sal G, et al. A genome-scale protein interaction profile of *Drosophila* p53 uncovers additional nodes of the human p53 network. *Proc Natl Acad Sci U S A*. 2010;107(14):6322–7.
60. Moriya S, Khel NB, Parhar IS. Cloning and serotonergic regulation of RING finger protein38 (rnf38) in the brain of medaka (*Oryzias latipes*). *Neuroscience*. 2015;294:109–15.
61. Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. *Nat Rev Genet*. 2016;17(12):719–32.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

